title: [Palliative therapy of primary liver tumors].
abstract: In Europe and North America, primary liver tumors are rare. Resection is the only means of cure, but is possible in only 20-30% of the patients affected, so that in all other patients, i.e. the vast majority, only palliative treatment is possible. In a retrospective analysis we investigated the 68 patients we had treated for hepatocellular or cholangiocellular carcinoma of the liver. In 14 patients resection was possible, while 28 patients were treated by chemoembolization and 26 by intraarterial regional chemotherapy to the liver. There was no difference in tumor stage between the two groups receiving different palliative treatments. The patients in whom resection was performed, in contrast, mostly had less advanced tumors. For chemoembolization we used a mixture of Ethibloc, mitomycin, Adriamycin and cisplatin. Up to 1986, the intraarterial chemotherapy was performed with mitomycin and 5-FU. Since 1986 we have used Adriamycin and cisplatin. The overall median survival time was 8 months: after resection 17 months, after chemoembolization 6.5 months, and after intraarterial chemotherapy 6.5 months. There was a significant difference in survival between patients with tumor stage II and those with tumor stages III and IV. On comparing the survival time achieved with our treatments and that ensuing in the natural course of patients with liver tumor we found no improvement.
authors.affiliation: Klinik für Allgemein- und Thoraxchirurgie, Justus-Liebig-Universität, Giessen.
authors.forename: C
authors.initials: C
authors.lastname: Kelm
authors.forename: K
authors.initials: K
authors.lastname: Henneking
authors.forename: T
authors.initials: T
authors.lastname: Zimmermann
authors.forename: M
authors.initials: M
authors.lastname: Vollerthun
authors.forename: W
authors.initials: W
authors.lastname: Padberg
mesh_terms: D002759:Adenoma, Bile Duct / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000792:Angiography; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D002272:Carcinoembryonic Antigen / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010166:Palliative Care; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D002272:Carcinoembryonic Antigen; D000509:alpha-Fetoproteins; D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil